Peptides Similar to LIB-01
Compare LIB-01 with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •Bremelanotide (PT-141): High - Both act on melanocortin receptor pathways to enhance sexual function through central nervous system mechanisms
- •Melanotan II: Moderate - Both engage melanocortin receptor pathways affecting sexual function, though through different mechanisms
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| LIB-01 (current) | - | - |
| Bremelanotide (PT-141) | High - Both act on melanocortin receptor pathways to enhance sexual function through central nervous system mechanisms | Bremelanotide is a cyclic peptide that directly agonizes MC1R/MC3R/MC4R and requires subcutaneous injection before each encounter. LIB-01 is an oral small molecule that modulates MC4R expression with a 3-day dosing course lasting 4-8 weeks. |
| Melanotan II | Moderate - Both engage melanocortin receptor pathways affecting sexual function, though through different mechanisms | Melanotan II is a non-selective cyclic peptide agonist activating MC1R/MC3R/MC4R/MC5R via subcutaneous injection. LIB-01 is an oral small molecule with selective MC4R modulation and much longer duration of action. |
Bremelanotide (PT-141)High - Both act on melanocortin receptor pathways to enhance sexual function through central nervous system mechanisms
Differences
Bremelanotide is a cyclic peptide that directly agonizes MC1R/MC3R/MC4R and requires subcutaneous injection before each encounter. LIB-01 is an oral small molecule that modulates MC4R expression with a 3-day dosing course lasting 4-8 weeks.
Advantages
Oral administration, dramatically longer duration of action (weeks vs hours), no need for pre-encounter dosing, potentially fewer melanocortin side effects due to pathway modulation vs direct agonism
Disadvantages
Investigational only (not FDA-approved), less clinical data, exact mechanism not fully elucidated, narrow indication focus (ED vs HSDD for bremelanotide)
Melanotan IIModerate - Both engage melanocortin receptor pathways affecting sexual function, though through different mechanisms
Differences
Melanotan II is a non-selective cyclic peptide agonist activating MC1R/MC3R/MC4R/MC5R via subcutaneous injection. LIB-01 is an oral small molecule with selective MC4R modulation and much longer duration of action.
Advantages
Oral dosing, MC4R selectivity (less tanning/pigmentation), sustained duration from short course, pharmaceutical-grade development through regulated clinical trials
Disadvantages
Investigational only, less accessible than research-grade melanotan II, limited to erectile dysfunction indication
Compounds Related to LIB-01#
LIB-01 occupies a unique position at the intersection of melanocortin pharmacology and sexual dysfunction therapeutics. While it is technically a small molecule (phragmalin limonoid) rather than a peptide, its mechanism of action through MC4R modulation places it in the same pharmacological family as melanocortin peptide therapeutics.
Bremelanotide (PT-141 / Vyleesi)#
Bremelanotide is the most clinically relevant comparator for LIB-01. It is a synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) that directly agonizes melanocortin receptors (MC1R, MC3R, MC4R) to enhance sexual function through central nervous system pathways. Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Mechanism comparison: Bremelanotide works through direct, transient receptor agonism with each dose. LIB-01 modulates MC4R expression and endogenous signaling, producing sustained pathway activation from brief exposure. This mechanistic distinction accounts for the dramatic difference in duration of action.
Clinical profile comparison:
| Parameter | LIB-01 | Bremelanotide (PT-141) |
|---|---|---|
| Route | Oral tablet | Subcutaneous injection |
| Dosing paradigm | 3 days, then 4-8 weeks effect | Before each sexual encounter |
| Onset | Within 7 days | 45 minutes |
| Duration | 4-8 weeks | 2-6 hours |
| Indication | ED (investigational) | HSDD in women (approved) |
| Key side effects | GI symptoms (mild, transient) | Nausea (40%), flushing, headache |
| FDA status | Phase 2 | Approved (2019) |
Key trade-off: Bremelanotide offers regulatory approval, proven efficacy, and availability now, but requires injection before each encounter and causes significant nausea. LIB-01 offers a potentially transformative dosing paradigm (oral, infrequent) but remains unproven beyond Phase 2a.
Melanotan II#
Melanotan II is a synthetic cyclic analog of alpha-MSH that non-selectively activates melanocortin receptors (MC1R through MC5R). It is widely available as a research peptide but is not FDA-approved for any indication. Users self-administer it subcutaneously for tanning and sexual enhancement.
Mechanism comparison: Melanotan II is a broad-spectrum melanocortin agonist producing multiple effects including skin darkening (MC1R), appetite suppression (MC4R), and sexual arousal (MC3R/MC4R). LIB-01's reported MC4R selectivity would theoretically produce sexual function enhancement without the tanning, appetite, and other off-target effects.
Safety consideration: Melanotan II's lack of regulatory oversight means no standardized quality control, dosing guidance, or long-term safety monitoring. LIB-01 is being developed through regulated clinical trials with pharmaceutical-grade manufacturing.
PDE5 Inhibitors (Indirect Comparison)#
While not melanocortin compounds, PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra) are the standard of care for ED and represent the primary competitive landscape for LIB-01.
Mechanism comparison: PDE5 inhibitors act peripherally on penile vascular smooth muscle by preventing cGMP degradation, enhancing the response to nitric oxide-mediated erection. LIB-01 acts centrally through MC4R to facilitate the neural initiation of erectile signaling. These are complementary rather than competing mechanisms.
Clinical profile comparison:
| Parameter | LIB-01 | PDE5 Inhibitors |
|---|---|---|
| Mechanism | Central (MC4R) | Peripheral (PDE5/cGMP) |
| Route | Oral | Oral |
| Dosing | 3 days per 4-8 weeks | Before each encounter (or daily) |
| Onset | Days | 30-60 minutes |
| Duration | Weeks | 4-36 hours |
| FDA status | Investigational | Approved (since 1998) |
| Efficacy evidence | Phase 2a (moderate) | Extensive (high) |
| PDE5 non-responders | May offer alternative | ~30% non-response rate |
LIB-01's central mechanism could benefit the approximately 30% of ED patients who do not respond adequately to PDE5 inhibitors, as non-response is often related to impaired neural signaling rather than vascular insufficiency.
Related Reading#
Frequently Asked Questions About LIB-01
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer